![](https://www.acepnow.com/wp-content/uploads/2024/06/priapism-fresco-featured-june-2024-1.png)
Dr. Westafer (@Lwestafer) is an attending physician and research fellow at Baystate Medical Center, clinical instructor at the University of Massachusetts Medical School in Worcester, and co-host of FOAMcast.
Explore This Issue
ACEP Now: Vol 43 – No 06 – June 2024References
- Bivalacqua TJ, Allen BK, Brock GB, et al. The diagnosis and management of recurrent ischemic priapism, priapism in sickle call patients, and nonischemic priapism: an AUA/SMSNA guideline. J Urol. 2022;208(1):43-52.
- Habous M, Elkhouly M, Abdelwahab O, et al. Noninvasive treatments for iatrogenic priapism: Do they really work? A prospective multicenter study. Urol Ann. 2016;8(2):193-196.
- Lowe FC, Jarow JP. Placebo-controlled study of oral terbutaline and pseudoephedrine in management of prostaglandin E1-induced prolonged erections. Urology. 1993;42(1):51-53.
- Govier FE, Jonsson E, Kramer-Levien D. Oral terbutaline for the treatment of priapism. J Urol. 1994;151(4):878-879.
- Ridyard DG, Phillips EA, Vincent W, et al. Use of high-dose phenylephrine in the treatment of ischemic priapism: Five-year experience at a single institution. J Sex Med. 2016;13(11):1704-1707.
- Sidhu AS, Wayne GF, Kim BJ, et al. The hemodynamic effects of intracavernosal phenylephrine for the treatment of ischemic priapism. J Sex Med. 2018;15(7):990-996.
Pages: 1 2 3 | Single Page
No Responses to “Updated Urology Guidelines for Priapism”